More on Current Evidences on Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease

authors:

avatar Pietro Vajro 1 , * , avatar Claudia Mandato 2 , avatar Roberta D’Aniello 1

Department of Medicine and Surgery, University of Salerno, Baronissi-Salerno, Italy
AORN Santobono Pediatric Hospital, Naples, Italy
Hepatitis Monthly: Vol.13, issue 8; e13780
published online: August 27, 2013
article type: Letter
received: July 24, 2013
revised: July 27, 2013
accepted: August 13, 2013
DOI: https://doi.org/10.5812/hepatmon.13780

how to cite: Vajro P, Mandato C, D’Aniello R. More on Current Evidences on Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease. Hepat Mon. 2013;13(8):e13780. https://doi.org/10.5812/hepatmon.13780.

Acknowledgements

References

  • 1.

    Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon. 2013;13(4). e7233. [PubMed ID: 23885277]. https://doi.org/10.5812/hepatmon.7233.

  • 2.

    Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Italian J Ped. 2012;38(1):55.

  • 3.

    Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol. 2008;42(10):1117-9. [PubMed ID: 18936646]. https://doi.org/10.1097/MCG.0b013e31816d920c.

  • 4.

    Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545-53. [PubMed ID: 21901256]. https://doi.org/10.1007/s10620-011-1887-4.

  • 5.

    Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12(2):256-62. [PubMed ID: 23396737].

  • 6.

    Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002;97(8):2144-6. [PubMed ID: 12190198]. https://doi.org/10.1111/j.1572-0241.2002.05942.x.

  • 7.

    Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540-3. [PubMed ID: 15942443].

  • 8.

    Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52(6):740-3. [PubMed ID: 21505361]. https://doi.org/10.1097/MPG.0b013e31821f9b85.

  • 9.

    Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56(5):461-8. [PubMed ID: 23287807]. https://doi.org/10.1097/MPG.0b013e318284abb5.

  • 10.

    Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120-7. [PubMed ID: 23401313]. https://doi.org/10.1002/hep.26319.

  • 11.

    Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9. [PubMed ID: 23055155]. https://doi.org/10.1002/hep.26093.